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My professional life over five decades meandered from a high school ambition to be a psychiatrist 
and understand the “mind” to biochemical studies of neurotransmitters and drugs. Hopefully, the 
tale of my quirky impatient curiosity about “too many” different areas will be useful for young 
scientists embarking on their own careers.My first professional interest was not in 
science but in psychiatry, based on a 
fascination with philosophy that began in 
high school. The summer before medical 
school I obtained a job at the National 
Institutes of Health (NIH), working on the 
metabolism of the amino acid histidine. 
I became hooked on research, spend-
ing all summers and elective periods in 
medical school at the NIH. Although still 
interested in clinical psychiatry, I was 
fortunate to obtain a research associate 
position at the NIH working with Julius 
Axelrod studying drugs and neurotrans-
mitters. Julie was an extraordinary men-
tor, and I opted for a career in “molecu-
lar psychiatry.” After the NIH, I went to 
Johns Hopkins for a psychiatry resi-
dency and then set up my laboratory and 
stayed. Other than summers in medical 
school, my sole scientific training com-
prised those 2 years in Julie’s laboratory. 
By contrast, present-day young bio-
medical scientists typically spend 5–8 
years in graduate school followed by two 
postdoctoral stints, each for half a dozen 
years. I fear that today’s prolonged train-
ing may stifle innate creativity, and so I 
would advocate for shorter rather than 
longer training periods, regardless of 
worries about being properly prepared to 
get a job or an NIH grant. Today’s young 
scientists worry that they need 5–6 years 
to publish a paper. With Julie, I published 
more than a half dozen full-length papers 
in respected journals in 2 years, which 
was not exceptional in those days.
When I set up my own laboratory at 
Johns Hopkins in 1966, I surveyed the 
world of molecular psychiatry. What path 
should I follow? Depression is the most 
common mental illness, afflicting roughly 
10% of the world’s population. The inci-
dence of schizophrenia is only about 1%, 1212 Cell 139, December 24, 2009 ©2009 Ebut most individuals with schizophre-
nia face a life of profound disability and, 
typically, from their 20s are never again 
productive citizens. By contrast, most 
depressed patients function reasonably 
well so that the morbidity from schizo-
phrenia is much greater. Moreover, the 
bizarre mental aberrations of schizophre-
nia pose fundamental questions about the 
nature of neuronal processes that underlie 
cognition and emotion. Despite the impor-
tance of mental illness, back then there 
were no reproducible findings of molecu-
lar abnormalities worth pursuing. Accord-
ingly, instead of plunging ahead to study 
the brains of psychiatric patients, I heeded 
one of Julie’s admonitions: “There are lots 
of important problems. Only attack those 
for which you can divine simple experi-
ments with clear answers.”
Instead of trying to solve the puzzle of 
schizophrenia, I chose a more modest 
goal, to learn more about neurotrans-
mitters and how they mediate actions of 
psychoactive drugs. Early work in our lab 
focused upon neurotransmitter uptake 
into the nerves that released them, the 
system for neurotransmitter inactivation 
first enunciated by Axelrod. We devel-
oped a simple approach to monitor 
transmitter uptake in nerve terminals in a 
relatively high-throughput fashion (Coyle 
and Snyder, 1969). During a visit to the 
Lilly Drug Company, I advocated the use 
of this screening procedure to differenti-
ate drugs inhibiting the reuptake of neu-
rotransmitters such as norepinephrine 
and serotonin. Lilly scientists subse-
quently used this approach to develop 
the first serotonin-selective uptake inhib-
itor fluoxetine (Prozac) (Kramer, 1993).
My early years as an independent 
researcher convey lessons that may 
be relevant to today’s young investiga-lsevier Inc.tors. I embarked upon a research direc-
tion that was quite unlike the pineal 
gland research that had been my focus 
in Julie’s laboratory. Doing something 
very different enabled me to establish 
my own psychological and professional 
identity. The work on drugs and neu-
rotransmitter uptake depended on new 
methodology. In my experience, simple, 
sensitive, and specific assays are the 
royal road to data acquisition. Acquiring 
abundant data in turn makes for discov-
ery. Too often, scientists slavishly follow 
methods cookbooks from the literature 
uncritically, when a few hours of critical, 
creative thinking could lead to new more 
efficient methods. Finally, I have always 
felt it is important to bear in mind the 
therapeutic relevance of basic research. 
The US Congress funds the NIH to dis-
cover causes of and cures for disease. 
Fundamental advances in knowledge, 
from the perspective of legislators, are 
merely byproducts. Never forget that, 
whether MD or PhD, we in the biomedi-
cal sciences are in the laboratory to help 
the sick.
In the early 1970s, much was known 
about biogenic amine neurotransmitter 
biosynthesis, metabolism, and transport. 
But at a molecular level little was known 
about neurotransmitter interactions with 
their receptors, the key feature of syn-
aptic signaling. The national focus upon 
heroin abuse impelled my lab to enter the 
opiate field, leading to the identification 
of opiate receptors by the simple bind-
ing of radiolabeled opiates to crude brain 
membranes (Pert and Snyder, 1973). This 
approach could be readily applied to all 
of the major neurotransmitters using 
tritiated drugs or the neurotransmit-
ters themselves. The receptor binding 
techniques that we developed trapped 
Table 1. Drug-Based and Other Research Strategies to Understand Psychosis
Dopamine Neuroleptics Relieve fundamental schizophrenic symptoms; 
act by blocking dopamine D2 receptors
Amphetamines/cocaine Mimic acute paranoid schizophrenic symptoms; 
release dopamine and/or inhibit its reuptake, 
inactivation
Polymorphisms in catechol 
O-methyltransferase (COMT), 
which metabolizes dopamine
Linked to executive function in schizophrenic 
patients
Glutamate Phencyclidine (PCP) Faithfully mimics schizophrenic symptoms; acts 
by blocking glutamate NMDA receptors
NMDA receptor agonists 
(glycine, D-serine) 




Relieves schizophrenic symptomsmembranes on small filters in a vac-
uum manifold permitting experiments 
with hundreds of test tubes a day. This 
enabled us to evaluate large numbers 
of drugs and to seek molecular expla-
nations for drug action. For instance, 
the relative potencies of antipsychotic 
neuroleptic drugs were shown to corre-
late with potencies in blocking a type of 
dopamine receptor, now designated D2. 
This fit with other evidence that the bio-
genic amine neurotransmitter dopamine 
is localized to neuronal systems that 
regulate cognition and emotions. Seda-
tive-hypotensive influences of the drugs 
reflected affinity for the α-adrenergic 
subtype of receptor for norepinephrine, 
known to regulate blood pressure and 
alertness. Drug affinities for the musca-
rinic subtype of the acetylcholine recep-
tor correlated inversely with extrapyra-
midal side effects that resemble those 
associated with the neurodegenerative 
disorder Parkinson’s disease. Knowing 
the receptors that mediate therapeutic 
and adverse effects of drugs permitted 
the rational design of more potent and 
safer therapeutic agents. Using different 
ligands it was then possible to discrimi-
nate subtypes of serotonin receptors 
(molecular cloning has now differenti-
ated 14) that mediate actions of diverse 
drugs ranging from antidepressants to 
anti-nausea agents.
When we identified opiate recep-
tors, some of my senior colleagues 
advised me to drop everything else and 
focus exclusively upon opiate addiction 
because of its fundamental importance 
to society. But I had no idea how to dis-
cover the molecular bases of addiction. 
Instead, I used the lessons taught by our opiate receptor work to define diverse 
neurotransmitter receptors and drug 
influences. My prejudice is to focus on 
problems that can be realistically solved 
while never discarding ultimate ideals 
that may not yet be achievable.
As “man was not born with morphine 
in him,” several groups including our 
own (Snyder, 1975) sought endogenous 
morphine-like substances leading to 
the elegant isolation by Hughes and 
Kosterlitz (Hughes et al., 1975) of the 
enkephalin pentapeptides. This work 
spawned studies identifying multiple 
peptides as neurotransmitters, a new 
chemical class in addition to biogenic 
amines and amino acid transmitters. The 
discovery in the late 1980s that a gas, 
nitric oxide (NO), occurs in biological tis-
sues and mediates blood vessel regula-
tion prompted investigations into NO as 
a neurotransmitter (Bredt and Snyder, 
1994). A neuron-specific form of NO syn-
thase converts arginine to NO and citrul-
line, and NO-forming neurons abound 
in the brain. In the peripheral nervous 
system, NO is a major neurotransmitter 
mediating numerous functions including 
penile erection. NO isn’t the only gas-
otransmitter. Carbon monoxide, formed 
from heme by heme oxygenase, also has 
transmitter properties (Boehning and 
Snyder, 2003). Very recently, compelling 
evidence has emerged that hydrogen 
sulfide is a messenger molecule medi-
ating endothelial-derived relaxing factor 
activity and mammalian blood pressure 
(Yang et al., 2008).
The discovery of new neurotransmit-
ters tells us much about how progress 
is made in the neurosciences and prob-
ably in most of the biological sciences. Cell 139, DWhen I was a medical student only two 
or three neurotransmitters were known. 
Most neurophysiologists felt that two 
would suffice, one for excitation and 
one for inhibition. The biogenic amines, 
such as dopamine, serotonin, and nor-
epinephrine, account for a relatively 
small proportion of neurons in the brain. 
Amino acids such as glutamate and 
γ-aminobutyric acid (GABA) together 
involve 90% of brain synapses. Thus, 
when peptides were identified as neu-
rotransmitters, many investigators felt 
that there wasn’t enough “room” in the 
brain for them. The finding that every 
neuron contains several neurotransmit-
ters helped to address this question. 
The subsequent identification of gases 
and D-amino acids, such as D-serine, as 
transmitters came as a big surprise. One 
central dogma of neurotransmission was 
that neurotransmitters must be stored in 
small synaptic vesicles and released by 
a unique process, “exocytosis,” whereby 
the vesicles fuse with the membranes 
of the nerve endings. The gaseous neu-
rotransmitters overturned this dogma as 
they cannot be locked up in vesicles. The 
gases overturned another “law” of neu-
rotransmission, that all neurotransmitters 
must act upon “receptors,” membrane 
proteins located on the external surface 
of adjacent cells. Not so for the gases, 
which merely diffuse into adjacent cells 
and, in the case of NO and hydrogen sul-
fide, chemically modify sulfhydryl groups 
of cysteines in target proteins. As for 
D-serine, it seemed to violate a central 
tenet of biology: D-sugar and L-amino 
acid stereospecificity. What does all of 
this teach us? Don’t be satisfied with 
established catechism. Rules are made 
to be broken. Go where questions take 
you even if you find yourself disputing 
scientific authority.
Might research on drugs and neu-
rotransmitters shed light on “causes” 
of mental illness (Table 1)? Some drugs 
mimic psychosis impressively, suggest-
ing that knowing their molecular mecha-
nisms of action will shed light on aberrant 
transmission in the brains of psychiatric 
patients. Thus, cocaine and amphet-
amines, which facilitate actions of dop-
amine, elicit a paranoid psychosis that 
resembles features of acute paranoid 
schizophrenia. Conversely, antipsychotic 
neuroleptic drugs act by blocking D2 ecember 24, 2009 ©2009 Elsevier Inc. 1213
dopamine receptors and are thought to 
relieve fundamental symptoms of schizo-
phrenia. These observations gave rise to 
the “dopamine hypothesis” of schizo-
phrenia, positing that excess dopamine 
neurotransmission plays some role in the 
neuropathophysiology of the illness. An 
increase in D2 dopamine receptors has 
been reported in the brains of unmedi-
cated schizophrenics, though these 
findings are controversial. There is better 
evidence that polymorphisms in the gene 
encoding the dopamine-metabolizing 
enzyme catechol O-methyltransferase 
(COMT) differentially mediate executive 
mental functions (Apud and Weinberger, 
2007). Normal individuals with a valine/
valine at amino acid 158 resulting in high 
COMT activity and hence less dopamine 
perform less well than individuals with 
methionine/methionine at amino acid 
158. These findings predict that COMT 
inhibitors that can penetrate the brain 
may be therapeutic.
The work on COMT illustrates a 
research strategy that commences with 
links between specific neurotransmit-
ters and drugs that influence schizo-
phrenia. It also demonstrates a powerful 
approach coordinating human genetics 
with behavioral studies in patients. The 
same research team recently carried out 
an even more ambitious effort linking 
schizophrenia to a specific potassium 
ion channel called KCNH2 (also called 
Herg) (Huffaker et al., 2009). Whereas the 
COMT studies compared two enzyme 
isoforms that are universally expressed, 
the new study identified an isoform of 
KCNH2 that occurs only in primates and 
is derived by alternative splicing virtu-
ally exclusively in the brain where it is 
expressed at much higher levels than the 
native channel. There followed genetic 
analysis comparing several thousand 
schizophrenic patients with healthy indi-
viduals, which revealed an association 
of single-nucleotide polymorphisms in 
KCNH2 with schizophrenia. Individuals 
with these polymorphisms display cog-
nitive abnormalities often associated 
with schizophrenia including lower IQ 
scores, slower cognitive processing, and 
even memory-associated abnormalities 
shown by functional MRI imaging. The 
hippocampus of postmortem schizo-
phrenic patients displayed substantially 
greater levels of the mutant KCNH2 1214 Cell 139, December 24, 2009 ©2009 Elpotassium channel than did the hip-
pocampus of healthy individuals. Finally, 
the authors demonstrated neurophysi-
ological differences in the mutant and 
wild-type ion channels, with the former 
inducing a rapidly deactivating potas-
sium current and a high-frequency non-
adapting neuronal firing pattern.
This potassium channel research illus-
trates some important concepts regard-
ing a search for the “cause” of mental 
illness. Conventional genetic analysis 
would never have unearthed the unique 
alternatively spliced isoform of the 
KCNH2 channel. Single-nucleotide poly-
morphism research itself would have 
been only of modest interest because 
the disease-control differences were not 
enormous. The concatenation of findings 
from multiple venues led to a compelling 
case for the importance of this altered 
potassium ion channel in schizophrenia.
Another approach to unraveling the 
mysteries of schizophrenia involves 
glutamate, the principal excitatory neu-
rotransmitter in the brain, which acts via 
its N-methyl-D-aspartate (NMDA) recep-
tor. Phencyclidine (PCP), a widely used 
illicit drug, elicits a psychosis that is 
often indistinguishable from schizophre-
nia. PCP, widely regarded as the best 
drug model of schizophrenia, acts by 
blocking NMDA receptors. Conversely, 
in clinical trials, agents that activate the 
so-called glycine site of NMDA recep-
tors—such as D-serine, D-cycloserine, 
and glycine itself—relieve the symptoms 
of schizophrenia. The NMDA receptor is 
“ionotropic,” incorporating an ion chan-
nel that is permeable to sodium and 
calcium ions. Metabotropic neurotrans-
mitter receptors are linked to G proteins 
and adenylyl cyclase or phospholipase 
C. Activation of metabotropic glutamate 
(mGluR) receptors, located on the nerve 
terminals of glutamate neurons, alters 
glutamate release. Recently, a drug 
(agonist) that stimulates the mGluR2 
glutamate receptor has been shown 
to alleviate schizophrenic symptoms 
as effectively as the well-established 
antipsychotic drug olanzapine (Patil et 
al., 2007).
But where to go next? This tale of 
drug-neurotransmitter research shows 
that one can make useful contribu-
tions even while failing to solve the so-
called big question, “What causes sevier Inc.schizophrenia, affective illness, and 
anxiety?” In pursuing my own career, 
might I have erred in not seeking these 
causes? Perhaps I was late in adopting 
the powerful techniques of molecular 
biology. Had I been more conversant 
with molecular genetics, perhaps I 
would have embarked on a search for 
genes underlying the major mental ill-
nesses. I follow the literature of this 
field and am entranced with each new 
advance. Identifying mutations in the 
genes encoding amyloid precursor 
protein and presenilins in familial forms 
of Alzheimer’s disease elegantly fits 
with abundant evidence for a role of the 
amyloid beta peptide in the much more 
frequent, sporadic forms of the illness. 
The discovery that mutations in DISC-1, 
a protein involved in axonal growth and 
neuronal positioning, are responsible 
for the schizophreniform and affec-
tive symptoms of several families with 
schizophrenia is tantalizing, as are 
reports of gene mutations that lead to 
autism (Chubb et al., 2008). I have faith 
that genes conferring a susceptibility 
to these illnesses will be unraveled in 
the not-too-distant future.
But there are caveats. Elegant and 
exhaustive genetic linkage studies in 
schizophrenia and affective disorder 
appear to indicate that no single genetic 
abnormality will account for a major por-
tion of the disease population (Psychi-
atric GWAS Consortium Coordinating 
Committee, 2009). Instead, very large 
numbers of rare mutations might con-
spire to influence disease development. 
In this case, it is hard to imagine how one 
could make use of the genetic data to 
link genes with brain dysfunction in the 
disease, to provide genetic counseling, 
and, most importantly, to develop gene-
based curative drugs.
Even in cases where we have defini-
tive genetic data, its translation to an 
understanding of pathophysiology and 
therapy may not be simple. The specific 
mutation underlying Huntington’s dis-
ease was reported in 1993 (The Hunting-
ton’s Disease Collaborative Research 
Group, 1993). The disease is caused 
by a mutation leading to large numbers 
of glutamine repeats in the ubiquitous 
protein huntingtin. Sixteen years later, 
we still don’t know the normal function 
of huntingtin nor do we have definitive 
insight into why this protein, expressed 
uniformly throughout the brain and all 
over the body, predominantly damages a 
single part of the brain, the corpus stria-
tum. Some insight into this question has 
come from recent protein binding stud-
ies showing that a striatal-specific small 
G protein, Rhes, interacts selectively 
with mutant huntingtin, SUMOylating it 
and disaggregating the mutant hunting-
tin protein resulting in cytotoxicity (Sub-
ramaniam et al., 2009). Drugs that block 
the binding of Rhes to mutant huntingtin 
might delay or even prevent the onset of 
brain damage.
Where is the field of molecular psy-
chiatry going? Molecular genetic stud-
ies of the major mental illnesses are 
becoming increasingly sophisticated. 
The possibility that there will be no 
single genes underlying major forms 
of the diseases is disconcerting. I sus-
pect that the “answers” may evolve in 
unexpected venues. For instance, the 
KCNH2 potassium ion channel story 
dealt with a gene that would not nor-
mally be linked strongly to schizo-
phrenia if one used the conventional 
methodology of examining genes in 
peripheral white blood cells. Instead, 
brain-specific alternative splicing was 
the key event. Perhaps further explo-
ration will reveal a multitude of such 
brain-specific molecular aberrations.
Using drugs as the starting point for 
finding disease abnormalities may bear 
fruit. Psychopharmacology offers the 
potential of major pay-offs long before 
one finds “causes” of disease. The con-
ventional antipsychotic drugs have been 
of immense benefit whether or not their 
action by blocking dopamine receptors 
tells us anything about schizophrenia. 
Research on dopamine provoked by the 
drug actions led to insights into dop-amine as an important neurotransmitter 
of cognitive functions mediated by the 
prefrontal area of the cerebral cortex, 
which has been implicated in the cogni-
tive disturbances of schizophrenia. This 
work also led to the discovery of cogni-
tive abnormalities associated with poly-
morphisms in COMT, the enzyme that 
metabolizes dopamine. New evidence 
showing that drugs that stimulate a glu-
tamate receptor subtype are as effective 
as earlier antipsychotic drugs will likely 
lead to a further escalation of research 
into glutamate as a critical neurotrans-
mitter in schizophrenia. In addressing 
these questions, I expect that large-
scale collaborative studies incorporating 
molecular, neurophysiological, genetic, 
and behavioral research will become 
more prevalent.
I have no surefire answers for young 
researchers seeking the “answer” 
to mental illness. One line of advice 
would be to heed advances in basic 
and clinical molecular genetics. How-
ever, I would eschew a direct “full-
back” attack to find the culprit gene. 
Instead, I might advocate the behavior 
of a “wide receiver,” taking advantage of 
clues from multiple seemingly unrelated 
sources, such as cancer, cardiovascu-
lar, and immunology research. The best 
insights often come from free-floating 
associations, which bring to bear on 
your problem what may seem to be “far 
out” sources. Most importantly, the new 
ideas should be testable in very simple 
experiments. Always design your exper-
iments to ensure that whatever you find 
will be useful whether or not it solves 
the big question. Finally, don’t plan your 
research to fit the supposed dictates 
of funding agencies—I’ve never done 
the experiments proposed in any of my 
grant applications. Good luck!Cell 139, DAcknowledgMents
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